Compare abrdn Income Credit Strategies Fund (ACP) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Alnylam Pharmaceuticals, Inc. — how do they compare? abrdn Income Credit Strategies Fund trades at $5.1 (market cap $641.16M), while Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 46.2× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 18.2% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ACP | ALNY | |
|---|---|---|
Market Cap | $641.16M | $29.60B |
Sector | Financials | Health |
52-Week High | $5.98 | $491.22 |
52-Week Low | $5.01 | $205.48 |
Dividend Yield | 18.2% | — |
Enterprise Value | — | $27.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.15 with a 1.38% daily gain, showing neutral technical signals with bearish moving averages. The stock maintains strong profitability with a 95.31% net income margin and attractive valuation at 7.74 P/E ratio. Recent dividend declarations of $0.08 per share demonstrate income focus, though revenue declined from $79M in 2024 to $42M in 2025 before projected recovery to $85M in 2026.
ACP presents a mixed outlook with sustainable dividends and undervalued metrics offset by revenue volatility and high leverage concerns. The 17% distribution rate faces sustainability questions with only 49% supported by net investment income. Investors should weigh the attractive yield against credit spread risks and global exposure in this high-beta closed-end fund.
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
